In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-03-08

AUTHORS

R. De Vecchis, C. Ariano, G. Di Biase, M. Noutsias

ABSTRACT

IntroductionIn heart failure with reduced left ventricular ejection fraction (HFREF) patients, the dosage of sacubitril/valsartan is modulated according to a gradual increase regimen. Nevertheless, if patients exhibit tolerability problems, a provisional reduction of the dose of sacubitril/valsartan or even its interruption are recommended.Material and methodsThis study provides estimates of respective proportions of patients receiving minimum or intermediate doses of sacubitril/valsartan. In addition, a comparison was made to detect possible differences regarding all-cause mortality and heart failure hospitalization in patients treated with the recommended optimum dose compared to those receiving submaximum maintenance doses of sacubitril/valsartan.ResultsPatients treated with sacubitril/valsartan in addition to beta-blocker and mineralocorticoid receptor blocker were 68. Among them, 20 patients (29.4%), were identified as having clinical features that were contraindications to the administration of sacubitril/valsartan at full dose. The subsequent decision was to maintain an intermediate dose in 11 patients and to reduce the dose to the minimum level allowed, i.e., 24 mg/26 mg twice daily in nine patients. After a median follow-up of 5.25 months, no differences were found concerning the risk of all-cause death by comparing patients treated with reduced versus those subjected to target doses of sacubitril/valsartan (odds ratio [OR] = 1.666; 95% confidence interval [CI] = 0.256–10.823; p = 0.6266). Patients taking reduced doses had a similar risk of heart failure hospitalizations when compared to patients treated with the target dose (OR = 0.789; 95% CI: 0.077–8.0808; p = 1.00).ConclusionDuring a median follow-up of 5.25 months, in the group of patients who had proven to be intolerant to the maximum dose of sacubitril/valsartan, use of reduced doses of the drug did not result in increased all-cause mortality or heart failure hospitalization compared to patients treated with sacubitril/valsartan at the target dose. More... »

PAGES

651-658

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-018-4690-6

DOI

http://dx.doi.org/10.1007/s00059-018-4690-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1101388657

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29520644


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aminobutyrates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitalization", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stroke Volume", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valsartan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ventricular Dysfunction, Left", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, ASL Napoli 1 Centro, via Cagnazzi\u00a029, 80137, Napoli, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Preventive Cardiologyand Rehabilitation Unit, DSB 29 \u201cS. Gennaro dei Poveri Hospital\u201d, via S.Gennaro dei Poveri\u00a025, 80136, Napoli, Italy", 
            "Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, ASL Napoli 1 Centro, via Cagnazzi\u00a029, 80137, Napoli, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Vecchis", 
        "givenName": "R.", 
        "id": "sg:person.0704361014.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Geriatrics, \u201cCasa Sollievo della Sofferenza\u201d Hospital, viale Cappuccini\u00a02, 71013, San Giovanni Rotondo, Italy", 
          "id": "http://www.grid.ac/institutes/grid.413503.0", 
          "name": [
            "Preventive Cardiologyand Rehabilitation Unit, DSB 29 \u201cS. Gennaro dei Poveri Hospital\u201d, via S.Gennaro dei Poveri\u00a025, 80136, Napoli, Italy", 
            "Division of Geriatrics, \u201cCasa Sollievo della Sofferenza\u201d Hospital, viale Cappuccini\u00a02, 71013, San Giovanni Rotondo, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ariano", 
        "givenName": "C.", 
        "id": "sg:person.0660263343.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Geriatrics, Clinic \u201cS. Maria del Pozzo\u201d, via Pomigliano\u00a040, 80049, Somma Vesuviana, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Geriatrics, Clinic \u201cS. Maria del Pozzo\u201d, via Pomigliano\u00a040, 80049, Somma Vesuviana, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Biase", 
        "givenName": "G.", 
        "id": "sg:person.01066703417.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066703417.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mid-German Heart Center, Department of Internal Medicine\u00a0III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst-Grube-Stra\u00dfe\u00a040, 06120, Halle, Germany", 
          "id": "http://www.grid.ac/institutes/grid.461820.9", 
          "name": [
            "Mid-German Heart Center, Department of Internal Medicine\u00a0III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst-Grube-Stra\u00dfe\u00a040, 06120, Halle, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noutsias", 
        "givenName": "M.", 
        "id": "sg:person.01077606445.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077606445.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00059-017-4671-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100478773", 
          "https://doi.org/10.1007/s00059-017-4671-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-03-08", 
    "datePublishedReg": "2018-03-08", 
    "description": "IntroductionIn heart failure with reduced left ventricular ejection fraction (HFREF) patients, the dosage of sacubitril/valsartan is modulated according to a\u00a0gradual increase regimen. Nevertheless, if patients exhibit tolerability problems, a\u00a0provisional reduction of the dose of sacubitril/valsartan or even its interruption are recommended.Material and methodsThis study provides estimates of respective proportions of patients receiving minimum or intermediate doses of sacubitril/valsartan. In addition, a\u00a0comparison was made to detect possible differences regarding all-cause mortality and heart failure hospitalization in patients treated with the recommended optimum dose compared to those receiving submaximum maintenance doses of sacubitril/valsartan.ResultsPatients treated with sacubitril/valsartan in addition to beta-blocker and mineralocorticoid receptor blocker were\u00a068. Among them, 20\u00a0patients (29.4%), were identified as having clinical features that were contraindications to the administration of sacubitril/valsartan at full dose. The subsequent decision was to maintain an intermediate dose in 11\u00a0patients and to reduce the dose to the minimum level allowed, i.e., 24\u202fmg/26\u202fmg twice daily in nine patients. After a median follow-up of 5.25\u00a0months, no differences were found concerning the risk of all-cause death by comparing patients treated with reduced versus those subjected to target doses of sacubitril/valsartan (odds ratio [OR]\u202f=\u202f1.666; 95% confidence interval [CI]\u202f=\u202f0.256\u201310.823; p\u202f=\u202f0.6266). Patients taking reduced doses had a similar risk of heart failure hospitalizations when compared to patients treated with the target dose (OR\u202f=\u202f0.789; 95%\u202fCI: 0.077\u20138.0808; p\u202f=\u202f1.00).ConclusionDuring a\u00a0median follow-up of 5.25\u00a0months, in the group of patients who had proven to be intolerant to the maximum dose of sacubitril/valsartan, use of reduced doses of the drug did not result in increased all-cause mortality or heart failure hospitalization compared to patients treated with sacubitril/valsartan at the target dose.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-018-4690-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "sacubitril/valsartan", 
      "heart failure hospitalization", 
      "cause mortality", 
      "target dose", 
      "reduced doses", 
      "ejection fraction patients", 
      "mineralocorticoid receptor blocker", 
      "group of patients", 
      "HFrEF patients", 
      "cause death", 
      "maintenance doses", 
      "receptor blockers", 
      "heart failure", 
      "tolerability problems", 
      "clinical features", 
      "intermediate dose", 
      "provisional reduction", 
      "similar risk", 
      "patients", 
      "hospitalization", 
      "full dose", 
      "low doses", 
      "intermediate doses", 
      "valsartan", 
      "maximum dose", 
      "doses", 
      "dose", 
      "mortality", 
      "optimum dose", 
      "months", 
      "possible differences", 
      "risk", 
      "respective proportions", 
      "ResultsPatients", 
      "regimen", 
      "contraindications", 
      "blockers", 
      "administration", 
      "death", 
      "drugs", 
      "differences", 
      "dosage", 
      "failure", 
      "group", 
      "proportion", 
      "interruption", 
      "subsequent decisions", 
      "addition", 
      "levels", 
      "study", 
      "minimum level", 
      "reduction", 
      "use", 
      "comparison", 
      "features", 
      "decisions", 
      "estimates", 
      "materials", 
      "problem", 
      "IntroductionIn heart failure", 
      "reduced left ventricular ejection fraction (HFREF) patients", 
      "left ventricular ejection fraction (HFREF) patients", 
      "ventricular ejection fraction (HFREF) patients", 
      "fraction (HFREF) patients", 
      "gradual increase regimen", 
      "increase regimen", 
      "failure hospitalization", 
      "submaximum maintenance doses", 
      "mg/26"
    ], 
    "name": "In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization", 
    "pagination": "651-658", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1101388657"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-018-4690-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29520644"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-018-4690-6", 
      "https://app.dimensions.ai/details/publication/pub.1101388657"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_767.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-018-4690-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-018-4690-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-018-4690-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-018-4690-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-018-4690-6'


 

This table displays all metadata directly associated to this object as RDF triples.

218 TRIPLES      22 PREDICATES      109 URIs      99 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-018-4690-6 schema:about N29df034e53f140d883d7d98a2fa94eea
2 N44c7a93ccc16424a915cc78d5d5fb1e2
3 N4964ef34226048e199e1f5cfd1a89ab0
4 N4f1420a7ec1144e783bbcc567ddcbea7
5 N68710c3eb28a4fcb96cd504e2a14934f
6 N69567d252df04588941ee463144a20cf
7 N715349b1ba1440e1959d078b7aa8faf5
8 N89365b9bb057422e8856c681a49737b9
9 N9ba91fb7625d42a085cc96a9653005e2
10 Nbb376e8854e54542ae15bc86b3d3a0a4
11 Nd1e2fc1bc1de48a088b544d4f35d4a76
12 Nfd0647a3742c4e9e90c904b7246bc41a
13 anzsrc-for:11
14 anzsrc-for:1102
15 anzsrc-for:1115
16 schema:author N464e204c1a354e859d03fe1a998bcbf2
17 schema:citation sg:pub.10.1007/s00059-017-4671-1
18 schema:datePublished 2018-03-08
19 schema:datePublishedReg 2018-03-08
20 schema:description IntroductionIn heart failure with reduced left ventricular ejection fraction (HFREF) patients, the dosage of sacubitril/valsartan is modulated according to a gradual increase regimen. Nevertheless, if patients exhibit tolerability problems, a provisional reduction of the dose of sacubitril/valsartan or even its interruption are recommended.Material and methodsThis study provides estimates of respective proportions of patients receiving minimum or intermediate doses of sacubitril/valsartan. In addition, a comparison was made to detect possible differences regarding all-cause mortality and heart failure hospitalization in patients treated with the recommended optimum dose compared to those receiving submaximum maintenance doses of sacubitril/valsartan.ResultsPatients treated with sacubitril/valsartan in addition to beta-blocker and mineralocorticoid receptor blocker were 68. Among them, 20 patients (29.4%), were identified as having clinical features that were contraindications to the administration of sacubitril/valsartan at full dose. The subsequent decision was to maintain an intermediate dose in 11 patients and to reduce the dose to the minimum level allowed, i.e., 24 mg/26 mg twice daily in nine patients. After a median follow-up of 5.25 months, no differences were found concerning the risk of all-cause death by comparing patients treated with reduced versus those subjected to target doses of sacubitril/valsartan (odds ratio [OR] = 1.666; 95% confidence interval [CI] = 0.256–10.823; p = 0.6266). Patients taking reduced doses had a similar risk of heart failure hospitalizations when compared to patients treated with the target dose (OR = 0.789; 95% CI: 0.077–8.0808; p = 1.00).ConclusionDuring a median follow-up of 5.25 months, in the group of patients who had proven to be intolerant to the maximum dose of sacubitril/valsartan, use of reduced doses of the drug did not result in increased all-cause mortality or heart failure hospitalization compared to patients treated with sacubitril/valsartan at the target dose.
21 schema:genre article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf N3091cd4dab084a20b1359a05527b0e83
25 Nbfc8ec19296e4ec88fbc4b899c2a8186
26 sg:journal.1087175
27 schema:keywords HFrEF patients
28 IntroductionIn heart failure
29 ResultsPatients
30 addition
31 administration
32 blockers
33 cause death
34 cause mortality
35 clinical features
36 comparison
37 contraindications
38 death
39 decisions
40 differences
41 dosage
42 dose
43 doses
44 drugs
45 ejection fraction patients
46 estimates
47 failure
48 failure hospitalization
49 features
50 fraction (HFREF) patients
51 full dose
52 gradual increase regimen
53 group
54 group of patients
55 heart failure
56 heart failure hospitalization
57 hospitalization
58 increase regimen
59 intermediate dose
60 intermediate doses
61 interruption
62 left ventricular ejection fraction (HFREF) patients
63 levels
64 low doses
65 maintenance doses
66 materials
67 maximum dose
68 mg/26
69 mineralocorticoid receptor blocker
70 minimum level
71 months
72 mortality
73 optimum dose
74 patients
75 possible differences
76 problem
77 proportion
78 provisional reduction
79 receptor blockers
80 reduced doses
81 reduced left ventricular ejection fraction (HFREF) patients
82 reduction
83 regimen
84 respective proportions
85 risk
86 sacubitril/valsartan
87 similar risk
88 study
89 submaximum maintenance doses
90 subsequent decisions
91 target dose
92 tolerability problems
93 use
94 valsartan
95 ventricular ejection fraction (HFREF) patients
96 schema:name In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization
97 schema:pagination 651-658
98 schema:productId Na72320e2a2ed43caa595ce45587ba340
99 Ncb0f267d850445a2b0aa650d1004d93a
100 Nf5ba1e661af944fcb5cc98173ff3ce75
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101388657
102 https://doi.org/10.1007/s00059-018-4690-6
103 schema:sdDatePublished 2022-01-01T18:47
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N73271e7c376f4758af2792bdf4b8c1fe
106 schema:url https://doi.org/10.1007/s00059-018-4690-6
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N29df034e53f140d883d7d98a2fa94eea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Ventricular Dysfunction, Left
112 rdf:type schema:DefinedTerm
113 N3091cd4dab084a20b1359a05527b0e83 schema:issueNumber 7
114 rdf:type schema:PublicationIssue
115 N3af54f4d0b594bc2a2a80802bd392070 rdf:first sg:person.0660263343.51
116 rdf:rest Nb7ea4d8f1a454a55ac3aa24c897aaf35
117 N44c7a93ccc16424a915cc78d5d5fb1e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Treatment Outcome
119 rdf:type schema:DefinedTerm
120 N464e204c1a354e859d03fe1a998bcbf2 rdf:first sg:person.0704361014.79
121 rdf:rest N3af54f4d0b594bc2a2a80802bd392070
122 N4964ef34226048e199e1f5cfd1a89ab0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Tetrazoles
124 rdf:type schema:DefinedTerm
125 N4f1420a7ec1144e783bbcc567ddcbea7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Valsartan
127 rdf:type schema:DefinedTerm
128 N68710c3eb28a4fcb96cd504e2a14934f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Stroke Volume
130 rdf:type schema:DefinedTerm
131 N69567d252df04588941ee463144a20cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Hospitalization
133 rdf:type schema:DefinedTerm
134 N715349b1ba1440e1959d078b7aa8faf5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Retrospective Studies
136 rdf:type schema:DefinedTerm
137 N73271e7c376f4758af2792bdf4b8c1fe schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 N89365b9bb057422e8856c681a49737b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Humans
141 rdf:type schema:DefinedTerm
142 N9145f0c4946c4b13865ac1c98f9bbfe7 rdf:first sg:person.01077606445.25
143 rdf:rest rdf:nil
144 N9ba91fb7625d42a085cc96a9653005e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Aminobutyrates
146 rdf:type schema:DefinedTerm
147 Na72320e2a2ed43caa595ce45587ba340 schema:name doi
148 schema:value 10.1007/s00059-018-4690-6
149 rdf:type schema:PropertyValue
150 Nb7ea4d8f1a454a55ac3aa24c897aaf35 rdf:first sg:person.01066703417.19
151 rdf:rest N9145f0c4946c4b13865ac1c98f9bbfe7
152 Nbb376e8854e54542ae15bc86b3d3a0a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Angiotensin Receptor Antagonists
154 rdf:type schema:DefinedTerm
155 Nbfc8ec19296e4ec88fbc4b899c2a8186 schema:volumeNumber 44
156 rdf:type schema:PublicationVolume
157 Ncb0f267d850445a2b0aa650d1004d93a schema:name pubmed_id
158 schema:value 29520644
159 rdf:type schema:PropertyValue
160 Nd1e2fc1bc1de48a088b544d4f35d4a76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Drug Combinations
162 rdf:type schema:DefinedTerm
163 Nf5ba1e661af944fcb5cc98173ff3ce75 schema:name dimensions_id
164 schema:value pub.1101388657
165 rdf:type schema:PropertyValue
166 Nfd0647a3742c4e9e90c904b7246bc41a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Heart Failure
168 rdf:type schema:DefinedTerm
169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
170 schema:name Medical and Health Sciences
171 rdf:type schema:DefinedTerm
172 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
173 schema:name Cardiorespiratory Medicine and Haematology
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
176 schema:name Pharmacology and Pharmaceutical Sciences
177 rdf:type schema:DefinedTerm
178 sg:journal.1087175 schema:issn 0340-9937
179 1615-6692
180 schema:name Herz
181 schema:publisher Springer Nature
182 rdf:type schema:Periodical
183 sg:person.01066703417.19 schema:affiliation grid-institutes:None
184 schema:familyName Di Biase
185 schema:givenName G.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066703417.19
187 rdf:type schema:Person
188 sg:person.01077606445.25 schema:affiliation grid-institutes:grid.461820.9
189 schema:familyName Noutsias
190 schema:givenName M.
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077606445.25
192 rdf:type schema:Person
193 sg:person.0660263343.51 schema:affiliation grid-institutes:grid.413503.0
194 schema:familyName Ariano
195 schema:givenName C.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660263343.51
197 rdf:type schema:Person
198 sg:person.0704361014.79 schema:affiliation grid-institutes:None
199 schema:familyName De Vecchis
200 schema:givenName R.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0704361014.79
202 rdf:type schema:Person
203 sg:pub.10.1007/s00059-017-4671-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100478773
204 https://doi.org/10.1007/s00059-017-4671-1
205 rdf:type schema:CreativeWork
206 grid-institutes:None schema:alternateName Cardiology Unit, Presidio Sanitario Intermedio “Elena d’Aosta”, ASL Napoli 1 Centro, via Cagnazzi 29, 80137, Napoli, Italy
207 Division of Geriatrics, Clinic “S. Maria del Pozzo”, via Pomigliano 40, 80049, Somma Vesuviana, Italy
208 schema:name Cardiology Unit, Presidio Sanitario Intermedio “Elena d’Aosta”, ASL Napoli 1 Centro, via Cagnazzi 29, 80137, Napoli, Italy
209 Division of Geriatrics, Clinic “S. Maria del Pozzo”, via Pomigliano 40, 80049, Somma Vesuviana, Italy
210 Preventive Cardiologyand Rehabilitation Unit, DSB 29 “S. Gennaro dei Poveri Hospital”, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy
211 rdf:type schema:Organization
212 grid-institutes:grid.413503.0 schema:alternateName Division of Geriatrics, “Casa Sollievo della Sofferenza” Hospital, viale Cappuccini 2, 71013, San Giovanni Rotondo, Italy
213 schema:name Division of Geriatrics, “Casa Sollievo della Sofferenza” Hospital, viale Cappuccini 2, 71013, San Giovanni Rotondo, Italy
214 Preventive Cardiologyand Rehabilitation Unit, DSB 29 “S. Gennaro dei Poveri Hospital”, via S.Gennaro dei Poveri 25, 80136, Napoli, Italy
215 rdf:type schema:Organization
216 grid-institutes:grid.461820.9 schema:alternateName Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst-Grube-Straße 40, 06120, Halle, Germany
217 schema:name Mid-German Heart Center, Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst-Grube-Straße 40, 06120, Halle, Germany
218 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...